| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Lyell Immunopharma Inc. Common Stock (NASDAQ: LYEL)
LYEL Technical Analysis
5
| As on 9th Jun 2023 LYEL STOCK Price closed @ 2.78 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 6.07 & Strong Sell for SHORT-TERM with Stoploss of 6.52 we also expect STOCK to react on Following IMPORTANT LEVELS. |
LYELSTOCK Price
| Open | 3.09 | Change | Price | % |
| High | 3.17 | 1 Day | -0.30 | -9.74 |
| Low | 2.78 | 1 Week | -0.11 | -3.81 |
| Close | 2.78 | 1 Month | 0.85 | 44.04 |
| Volume | 818111 | 1 Year | -5.56 | -66.67 |
| 52 Week High 8.95 | 52 Week Low 1.89 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| LYEL Daily Charts |
LYEL Intraday Charts |
Whats New @ Bazaartrend |
LYEL Free Analysis |
|
|
LYEL Important Levels Intraday
| RESISTANCE | 3.53 |
| RESISTANCE | 3.29 |
| RESISTANCE | 3.14 |
| RESISTANCE | 2.99 |
| SUPPORT | 2.57 |
| SUPPORT | 2.42 |
| SUPPORT | 2.27 |
| SUPPORT | 2.03 |
LYEL Forecast April 2024
| 4th UP Forecast | 7.21 |
| 3rd UP Forecast | 5.79 |
| 2nd UP Forecast | 4.91 |
| 1st UP Forecast | 4.03 |
| 1st DOWN Forecast | 1.53 |
| 2nd DOWN Forecast | 0.65 |
| 3rd DOWN Forecast | -0.23 |
| 4th DOWN Forecast | -1.65 |
LYEL Weekly Forecast
| 4th UP Forecast | 5.84 |
| 3rd UP Forecast | 4.86 |
| 2nd UP Forecast | 4.25 |
| 1st UP Forecast | 3.65 |
| 1st DOWN Forecast | 1.91 |
| 2nd DOWN Forecast | 1.31 |
| 3rd DOWN Forecast | 0.70 |
| 4th DOWN Forecast | -0.28 |
LYEL Forecast2024
| 4th UP Forecast | 16.21 |
| 3rd UP Forecast | 11.9 |
| 2nd UP Forecast | 9.24 |
| 1st UP Forecast | 6.58 |
| 1st DOWN Forecast | -1.02 |
| 2nd DOWN Forecast | -3.68 |
| 3rd DOWN Forecast | -6.34 |
| 4th DOWN Forecast | -10.65 |
Lyell Immunopharma Inc. Common Stock ( NASDAQ USA Symbol : LYEL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
LYEL Business Profile
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Address: 400 East Jamie Court, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service